The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...
Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of ...
Looking for something new to do or learn this winter? The following programs, taught or led by residents, are sponsored by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results